The Cancer Breakthrough scene is heating up like no Man’s business.
The significance and Context of 2025 Chinese expert consensus on Multi Cancer Early Detection, in China to date .
The 2025 Chinese expert consensus (“Expert consensus on liquid biopsy based multi cancer early detection (2025 edition)”) appears to be the first and only formal national‐level consensus referencing MCED (Multi Cancer Early Detection) in China to date .
⸻
Overview of the Consensus
• Published: July 23, 2025, in Zhonghua Zhong Liu Za Zhi .
• Issued by: The Working Group for Liquid Biopsy–based MCED, associated with the National Cancer Center, Peking Union Medical College, and Tianjin Medical University Cancer Institute .
⸻
Key Highlights and Insights
1. Rationale and Scope
• Recognizing that traditional single cancer screening methods are limited—being invasive, less accurate, and having low patient compliance.
• MCED via liquid biopsy offers a noninvasive and efficient approach for early detection of multiple cancers by analyzing cfDNA, cfRNA, proteins, and metabolites .
2. What the Consensus Covers
• A comprehensive review of:
• Technological advances in liquid biopsy based MCED
• Criteria for biomarker selection
• Strategies for cancer type inclusion
• Research and validation designs
• Guidance on clinical utility evaluation
• Implementation pathways and integration into healthcare systems .
3. Goal and Impact
• Aims to furnish scientific guidance for research and broad, effective implementation of MCED tests in China.
• Intended to optimize cancer screening strategies, potentially influencing policy, clinical practice, and translational research .
⸻
Broader Context: How It Relates to OncoSeek and Global MCED Trends
• OncoSeek is a blood-based, AI driven MCED test developed by SeekIn. It uses seven protein tumor markers (e.g., AFP, CEA, CYFRA21 1), along with age and sex, to detect multiple cancers and predict tissue of origin .
• Proven performance in large-scale studies (~9,382 participants): ~51.7% sensitivity, ~92.9% specificity, ~84.3% overall accuracy; tissue-of-origin identified correctly ~66.8% of the time .
• Remarkably low cost (~$20/test) and designed to run on widely available lab analyzers, making it suitable for LMICs .
• SeekIn has also proposed a two-step screening strategy—initial OncoSeek, followed by genomic confirmation (SeekInCare)—dramatically reducing false positives and costs compared to single-step MCED approaches .
• While the 2025 consensus isn’t tied to OncoSeek specifically, it lays the groundwork for technologies like it by:
• Establishing standards and scientific criteria for biomarker panels and validation methods.
• Framing implementation pathways that MCED technologies must navigate for clinical adoption.
• On the global stage, MCED is gaining attention:
• Systematic reviews cite sensitivities of 50–95% and specificities of 89–99% for various MCED assays, but emphasize challenges in accuracy, ethics, healthcare integration, and need for multi-institutional validation .
• The American Cancer Society notes MCED tests are not yet FDA approved; they should complement, not replace, conventional screening, and require further research .
⸻
Final Thoughts
• The Chinese expert consensus represents a pivotal milestone—it’s the first national-level MCED framework in China and will likely influence future clinical, regulatory, and research directions.
• OncoSeek, with its design aligning with the consensus’s principles, stands out as a prime candidate for implementation and real-world impact.
• As MCED evolves globally—from trials to clinical adoption—China’s consensus could serve as a model for other countries developing their own guidelines.
**[SHARE THIS IF YOU BELIEVE EARLY DETECTION IS THE REAL CURE]**
**#CancerRevolution #MCED #OncoSeek #LiquidBiopsy #ChinaHealth #EarlyDetectionSavesLives #FutureOfMedicine**
**BWS OUT.**
*(P.S. The best time to catch cancer was 10 years ago. The second-best time? Right now.)*
HOW TO CONSULT WITH BWS?
Rates: $100 | 30 minute
Contact: TO PARTNER OR FOR CONSULTATION
Emeritus Prof Ifeoma Okoye
Email: sales@slaynetwork.co.uk
Website: https://slaylebrity.com/users/pinkyprof/
Instagram: @pinkyprof_wellness
PS: If you will like to join Slaylebrity VIP social network pls contact sales@slaynetwork.co.uk and include referred by BWS in your subject cheers!
China just changed the game. Not with a missile. Not with a viral meme. But with a consensus now impacting positively the framework for **blood tests**
On **July 23, 2025**, something historic happened. Quietly. Without fanfare.
China released the **first national expert consensus** on **Multi-Cancer Early Detection (MCED)** — a unified, science-backed roadmap for catching cancer *before* it destroys lives.
This isn’t just another medical paper. This is a **national strategy**. A **wake-up call**. A signal that the future of cancer care has arrived — and it’s not coming from the West.
For decades, cancer screening has been slow, invasive, and fragmented. Colonoscopy. Mammogram. PSA test. One organ at a time. Low compliance. Late detection. And by the time most people get diagnosed? **It’s already too late.**
But now, China has officially endorsed a new path: **Liquid biopsy. One blood draw. Multiple cancers. Detected early.**
While the 2025 consensus isn’t tied to OncoSeek specifically, it lays the groundwork for technologies like it by: • Establishing standards and scientific criteria for biomarker panels and validation methods.
